Brought to you by 
Ortho-McNeil gets rights to Addex's neurology compounds
17 Dec 2014
Executive Summary
Addex Pharmaceuticals SA (developing therapeutics for CNS disorders) has granted Johnson & Johnson's Ortho-McNeil Pharmaceutical division exclusive worldwide rights to its ADX2 and ADX3 series of compounds that the two will jointly discover and develop. The companies will create drug candidates, which Ortho-McNeil will market, to modulate allosterical G-protein coupled receptors to treat anxiety, depression, schizophrenia, and Alzheimer's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ortho-McNeil gets rights to Addex's neurology compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice